LDS/Medical Tests/Circulating Tumor Cells (CTC), Colon Cancer

Circulating Tumor Cells (CTC), Colon Cancer

The Circulating Tumor Cell (CTC) test provides a measurement of tumor cells (cancer) that are circulating in the bloodstream. It provides enumeration of circulating tumor cells (CTC) of epithelial origin in whole blood originating from tumors/cancers. The circulating tumor cells are of epithelial origin and are not normally found in blood and are extremely rare in individuals with no malignancy. Since tumor cells have a tendency to metastasize, blood would be one of the travel routes. Therefore, CTCs are mainly found in metastatic cancers. The CTC test measures the number of tumor cells that are circulating freely in the bloodstream. This assay uses specific markers to detect epithelial tumor cells in blood, and it is specific for epithelial cell tumor markers of colon cancer origin. The results of this test are utilized to determine the efficacy of treatment (such as chemotherapy) and prognosis of patients with metastatic cancer of the colon. Studies indicate that results of fewer than 2 CTCs has a mean survival rate of 18 months. Greater than or equal to 3 CTCs is predictive of shorter progression-free survival (PFS) and poorer overall survival (OS) for metastatic colon cancer patients. These individuals have a survival rate of approximately 7 months. Detecting the presence of circulating tumor cells in blood shows clinical usefulness in the assessment of disease status and prognosis in patients with metastatic colon cancer.

  • Disease treatment management and efficacy of treatment (such as chemotherapy) and prognosis of patients with metastatic cancer of the colon
  • Circulating Tumor Cell results assist the physician in predicting the advanced colon cancer patient's response to treatment and overall survival rate

Increased in:

  • Metastatic colon cancer
  • Colon cancer

 <3 CTCs/7.5 mL whole blood (Negative for CTC)

 

 

CellSearch(R), Immunomagnetic selection, identification and enumeration of CTC in peripheral blood sample enrichment.

10 mL room-temperature whole blood (CellSave Preservative Tube); 7.5 mL minimum volume. Ship promptly; specimen must be tested within 96 hours. Provide collection date and time. Do not refrigerate. Patient history pertinent to colon cancer is required to perform this test. Please include all relevant clinical information on the test request form. Patients on doxorubicin (Adriamycin) must wait a minimum of 7 days after administration before blood is drawn for this test.

Carcinoembryonic Antigen (CEA), B-RAF mutation analysis, Microsatellite Instability/HNPCC by molecular method and by IHC, Occult blood.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login